Prostate Cancer

Deepak A. Kapoor, MD, president of the Large Urology Group Practice Association, provides his opinion on current prostate cancer screening recommendations.

Michael J. Morris, MD, medical oncologist, Genitourinary Oncology Service, Memorial Sloan-Kettering Cancer Center, discusses the use of radiographic progression-free survival as an endpoint in prostate cancer clinical trials.

Howard M. Sandler, MD, discusses the RTOG 94-06 study, which analyzed three dimensional conformal radiation therapy and intensity-modulated radiation therapy (IMRT) for patients with prostate cancer.

E. David Crawford, MD, describes his excitement over the potential for novel combinations and sequences in the treatment of patients with castration-resistant prostate cancer.

Susan F. Slovin, MD, PhD, from Memorial Sloan-Kettering Cancer Center, provides an overview of the most promising immunotherapeutic follow-ups to sipuleucel-T in prostate cancer.

Lawrence Karsh, MD, from The Urology Center of Colorado, discusses strategies for sequencing treatments for men with metastatic castration-resistant prostate cancer.

Michael J. Morris, MD, medical oncologist, Genitourinary Oncology Service, Memorial Sloan-Kettering Cancer Center, discusses the use of PET imaging for patients with prostate cancer.

The FDA approved radium RA 223 dichloride for the treatment of symptomatic metastatic castration-resistant prostate cancer that has spread to the bones but not to any other organs.

Howard I. Scher, MD, from the Memorial Sloan-Kettering Cancer Center, discusses an updated analysis of the COU-AA-302 trial, which examined treatment with abiraterone in men with mCRPC prior to the administration of chemotherapy.

The treatment of bone metastases in prostate cancer has changed over the years, and several options are now either available or under development.

Mark C. Scholz, MD, from Prostate Oncology Specialists Inc, describes his excitement over advances in prostate cancer imaging techniques, specifically those involving multiparametric MRI.

Several case studies highlighting the latest strategies and therapeutic agents available for patients with prostate cancer.

The American Urological Association outlines clinical guidelines for sequencing castration-resistant prostate cancer therapies based on six "index patients" each with specific disease characteristics.

The 108th AUA Annual Meeting held May 4-8 in San Diego, California, contained over 2,000 presentations focused on urologic medicine. This entry contains summaries of four abstracts focused on urothelial, testicular, and prostate cancer.

Expectant management, which includes active surveillance and watchful waiting, is widely underused in the treatment of prostate cancer in the United States.

Daniel P. Petrylak, MD, from the Smilow Cancer Center at Yale-New Haven, describes the clinical investigation of the immunotherapeutic vaccine PROSTVAC in men with castration-resistant prostate cancer.

Howard M. Sandler, MD, from the Cedars-Sinai Medical Center, describes his excitement over research into new agents that modulate the androgen axis in prostate cancer.

A large, international study has yielded a wealth of new information about genetic alterations that can increase an individual's risk of breast, prostate, and ovarian cancer.

Studies that continue to shed light on the optimal use of sipuleucel-T in men with prostate cancer were presented at the 2013 Genitourinary Cancers Symposium.

E. David Crawford, MD, from the University of Colorado, Anschutz Medical Campus, discusses the rapidly changing treatment landscape for men with advanced prostate cancer.

Robert Dreicer, MD, MS, from the Cleveland Clinic in Ohio, discusses challenges facing the development of new lyase inhibitors and androgen receptor antagonists as treatments for men with prostate cancer.

Digital rectal examination should remain a standard for screening for prostate cancer and may even be able to identify cases of the disease that are not picked up by the PSA test.

Leonard G. Gomella, MD, form the Thomas Jefferson University Hospital Kimmel Cancer Center, discusses the novel therapeutic radium-223, which is awaiting a decision from the FDA as a treatment for men with advanced prostate cancer.

Daniel P. Petrylak, MD, from the Smilow Cancer Center at Yale-New Haven, describes a phase I/II study examining the safety and efficacy of orteronel in combination with docetaxel and prednisone in metastatic castration-resistant prostate cancer.

E. David Crawford, MD, from the University of Colorado, Anschutz Medical Campus, discusses the effectiveness of the immunotherapy sipuleucel-T as a treatment for men with advanced prostate cancer.

Robot-assisted radical prostatectomy adoption into medical practice has been swift and encompassing, even as questions remain about its efficacy, added costs, and perioperative and longer-term outcomes versus alternatives.

Howard M. Sandler, MD, the Chair of Radiation Oncology at Cedars-Sinai Medical Center, discusses radium-223, a novel alpha radiation emitting agent under evaluation by the FDA for patients with bone metastases from advanced castration-resistant prostate cancer (CRPC).

Leonard G. Gomella, MD, from the Thomas Jefferson University Hospital Kimmel Cancer Center, discusses the information currently available on sequencing the recently approved treatments for men with metastatic castration-resistant prostate cancer.

15 years after treatment, patients have roughly equal odds of experiencing declines in functions, with no significant difference associated with their choice of either radical prostatectomy or external-beam radiation therapy.

Daniel P. Petrylak, MD, from the Smilow Cancer Center at Yale-New Haven, discusses the relationship between sipuleucel-T and time to first use of an opioid analgesic in patients with metastatic castration-resistant prostate cancer.